Rising numbers of attention deficit hyperactivity disorder (ADHD) referrals and diagnoses have prompted important questions about how ADHD is assessed, how services should respond and how people can receive appropriate support. In 2026, that discussion intensified following a controversial Channel 4 documentary and the publication of a major government-commissioned review into the condition. These controversies have detracted from a core fundamental aspect: ADHD is recognised as a neurodevelopmental condition supported by decades of scientific research and evidence. The discussion should not be related to the validity of this diagnosis, but on the most effective and evidenced-based assessment and treatment approaches to support affected individuals.
The question is therefore not whether ADHD exists, but how we can ensure that people experiencing difficulties receive high-quality assessment and the right support at the right time.
What is ADHD?
ADHD is a neurodevelopmental condition associated with persistent difficulties involving attention, impulsivity and, for some people, hyperactivity. It can also affect organisation, time management and emotional regulation.
Decades of international research show ADHD exists. A major international consensus statement published in 2021 brought together hundreds of evidence-based findings on ADHD [1]. Genetics play an important role with family studies indicating the high heritability of ADHD, while large-scale genomic research has identified multiple genetic variants associated with the condition [2,3]. This is supported by brain-imaging studies reporting differences in aspects of brain development when groups of people with ADHD are compared with those without ADHD [4].
Is ADHD ‘treatable’?
Here at Bloomfield Health, we avoid framing ADHD as something to be treated; instead, we are focused on understanding the person’s individuality and helping them manage difficulties, including the friction that arises from living in a neurotypical world not set up for their needs. We aim to effectively help the individual live the type of life they want to live, reducing or minimising aspects of their ADHD which they may find unhelpful or disruptive.
Medication is an option that can be explored. A large systematic review and network meta-analysis published in The Lancet Psychiatry, for example, found evidence supporting the effectiveness of several ADHD medications [5].
But medication is only one part of care. Depending on the individual, support may also include:
Treatment should always be personalised, taking account of a person’s circumstances, preferences, physical health and any other mental health or neurodevelopmental needs.
Why has ADHD become so controversial?
The increase in ADHD referrals and diagnoses has led to debates about the consistency and quality of assessment. These questions reached a wider audience in August 2026 when Channel 4 broadcast The Great ADHD Myth?. The programme questioned whether ADHD should be understood as a genuine neurodevelopmental disorder or as a label applied to behaviours that might otherwise be considered part of normal variation.
The documentary generated substantial criticism. ADHD researchers and professional organisations argued that its presentation did not adequately reflect the weight of scientific evidence supporting ADHD as an established neurodevelopmental condition [6,7]. In addition, surveys launched after the programme described how 94% of respondents said the show had increased stigma relating to ADHD.
Concerns about overdiagnosis, variable assessment standards or inappropriate prescribing could be points for further discussion and research but should be examined carefully. High-quality ADHD care depends on comprehensive assessment and responsible prescribing.
What did the 2026 UK government review conclude?
A further development came on 9 October 2026, with the publication of the independent government-commissioned review into mental health conditions, ADHD and autism, chaired by Professor Peter Fonagy [8].
The review offers a more nuanced framework for understanding the current situation, recognising the genetic basis of ADHD whilst also exploring the substantial increase in referrals and diagnoses, without concluding widespread overdiagnosis as a prominent factor.
The review establishes important recommendations to move towards a “needs-led plus diagnosis” approach. This means that the review recommends people should not have to wait for a formal diagnosis before receiving help with difficulties that are already affecting their education, work, relationships or wellbeing.
At the same time, specialist diagnostic assessment remains important where it can guide treatment and help people understand their difficulties. This recognises that support and diagnosis can serve related but distinct purposes.
Better assessment, not simply more diagnosis
The review also highlights the importance of improving standards across ADHD and neurodevelopmental services. Recommendations include better-integrated services, stronger oversight and regulation, appropriate specialist provision, and greater attention to people’s overall needs rather than viewing diagnosis as the sole gateway to help [8,9].
Some people seeking an ADHD assessment may also experience anxiety, depression, trauma-related difficulties, sleep problems or other neurodevelopmental conditions. A thorough psychiatric assessment therefore needs to consider the whole person rather than simply determine whether someone meets a diagnostic checklist.
The cost of unsupported ADHD
Getting ADHD care right matters not only clinically but socially and economically. NHS England’s Independent ADHD Taskforce estimated that unsupported ADHD is associated with economic costs of at least £17 billion a year in the UK [10]. Representing wider estimated costs associated with areas including education, employment, healthcare and public services.
For individuals, the consequences can be considerable. Difficulties with concentration, organisation, deadlines, impulsivity or emotional regulation can affect education, careers, relationships and self-esteem. Earlier recognition, effective treatment and appropriate adjustments may therefore have benefits extending well beyond symptom reduction.
Bloomfield Health’s approach to ADHD
At Bloomfield Health, our approach is consistent with many of the principles highlighted by the 2026 review: careful assessment, personalised treatment and consideration of the individual’s wider psychological, social and occupational circumstances.
Our multidisciplinary team provides ADHD assessment and treatment, including medication management, psychological therapies and practical support where appropriate.
Bloomfield Health also has expertise in occupational health assessment, allowing us to consider how ADHD and other mental health or neurodevelopmental conditions may affect someone at work. This can include advice about reasonable adjustments, managing workplace difficulties and supporting a return to work.
The emerging emphasis on needs-led care also creates an opportunity to develop increasingly integrated ADHD pathways: combining accurate diagnosis when required with timely practical support, appropriate treatment and a sustained focus on improving everyday functioning.
Moving the ADHD debate forward
ADHD is a scientifically established neurodevelopmental condition for which effective support and treatment exists. At the same time, every diagnosis should be based on a robust assessment, and care should be tailored to the individual. The 2026 government review offers an opportunity to move beyond a polarised debate, focusing on adaptive treatment approaches that reduce stigma and facilitate earlier and more effective support.
How Bloomfield Health can help
If you are considering an ADHD assessment, looking for support before or following a diagnosis, or need specialist advice about ADHD and mental health in the workplace, Bloomfield Health can provide an individualised assessment and discuss appropriate next steps.
Learn more about our ADHD assessment and treatment services or contact Bloomfield Health to discuss your needs.
This article is for general information and does not replace individual medical advice, diagnosis or treatment. Clinical decisions should be made following an appropriate assessment by a suitably qualified healthcare professional.
References
We are registered by the Care Quality Commission (CQC),
the independent regulator of health and social care in England.
